7D2A Stock Overview
A medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sedana Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.57 |
| 52 Week High | SEK 2.39 |
| 52 Week Low | SEK 0.88 |
| Beta | 0.34 |
| 1 Month Change | 6.10% |
| 3 Month Change | 54.74% |
| 1 Year Change | 8.22% |
| 3 Year Change | -72.67% |
| 5 Year Change | -53.39% |
| Change since IPO | -20.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7D2A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -2.4% | -0.6% |
| 1Y | 8.2% | -4.7% | 14.8% |
Return vs Industry: 7D2A exceeded the German Medical Equipment industry which returned -5.1% over the past year.
Return vs Market: 7D2A underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| 7D2A volatility | |
|---|---|
| 7D2A Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 7D2A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7D2A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 109 | Johannes Doll | www.sedanamedical.com |
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; and Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care, as well as AnaConDa, a medical device enabling administration of inhaled anaesthetics. It also provides FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; Scavenging tube, a one piece pre-connected tube designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; FlurAbsorb mount to hold the FlurAbsorb during scavenging of anesthetic gas; FlurAbsorb-S mount to hold the FlurAbsorb-S during scavenging of anesthetic gas; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and Mindray exhaust connector, which enables to connect the exhaust of the ventilator to an active or passive scavenging system.
Sedana Medical AB (publ) Fundamentals Summary
| 7D2A fundamental statistics | |
|---|---|
| Market cap | €159.36m |
| Earnings (TTM) | -€959.87k |
| Revenue (TTM) | €16.07m |
9.9x
P/S Ratio-166.0x
P/E RatioIs 7D2A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7D2A income statement (TTM) | |
|---|---|
| Revenue | SEK 178.75m |
| Cost of Revenue | SEK 52.61m |
| Gross Profit | SEK 126.14m |
| Other Expenses | SEK 136.82m |
| Earnings | -SEK 10.67m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 11, 2025
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 70.57% |
| Net Profit Margin | -5.97% |
| Debt/Equity Ratio | 0% |
How did 7D2A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 03:11 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sedana Medical AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Östling | Pareto Securities |
| Filip Wiberg | Pareto Securities |
| Oscar Bergman | Redeye |